- About Us
- Media Release
- Our Clients
- Media Mentions
- Subscription Model
- Contact Us
The Global Uveitis Treatment Market size is expected to reach $686.1 Million by 2025, rising at a market growth of 5.5% CAGR during the forecast period. Uveitis is the inflammation of the middle tissue layer in the uvea eyewall which consists of the iris, choroid, and ciliary body. Various drug formulations such as anti-inflammatory drugs, cycloplegic agents, antimicrobial drugs, immunotherapy & targeted therapies, and others are used for uveitis treatment. These involve anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis. Inflammation of the iris called iritis or anterior uveitis is the most prevalent form of uveitis.
Global Uveitis Treatment Market Size
Increased prevalence of uveitis and growing awareness among the patient population with increased acceptance of innovative treatments is expected to drive the growth of the market. In addition, convenient access to uveitis treatment, increased demand for uveitis medications, and a boom in R&D activities to improve ideal uveitis treatment to further drive the growth of the industry.
Nevertheless, it is anticipated that the uncertain etiology and pathophysiology of uveitis would hinder market development. In addition, untapped capacity offered by emerging economies is presenting lucrative opportunities for market growth over the forecast period. Nonetheless, there is likely to be a shortage of effective treatment for uveitis disorder to limit the market growth.
Uveitis Treatment Market Share
Uveitis is considered the leading cause of blindness in the United States, with a steady rise in prevalence. Corticosteroid is considered the first-line treatment for uveitis. A large number of compounds for treating uveitis are lined up in growth. Leading industry players are adding new drugs to improve their product portfolio. The procedure for the sterile formulations, however, is highly complex and businesses are likely to align themselves with the GMP and regulatory requirements for producing their products.
Based on Drug Class, the market is segmented into Anti-inflammatory, Immunotherapy & Targeted Therapies, Antimicrobial Drugs and Other Drug Class. Based on Disease Type, the market is segmented into Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis and Panuveitis. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online stores. Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa.
Free Valuable Insights: Global Uveitis Treatment Market to reach a market size of $686.1 million by 2025
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Alimera Sciences, Inc., Enzo Biochem, Inc., Amgen, Inc., Bausch Health Companies, Inc., Clearside Biomedical, Inc., EyePoint Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., TopiVert Ltd., and Novartis AG.
By Drug Class
By Disease Type
By Distribution Channel
According to a new report published by KBV Research, The global uveitis treatment market size is expected to reach $686.1 million by 2025.
The market is expected to witness a boost due to rising incidence of anterior uveitis, R&D Efforts Focusing on Non-steroidal Injectables, and A rise in the development of innovative biologics. The market growth is expected to get affected due to impact of coronavirus outbreak on healthcare supply chains.
The expected CAGR of uveitis treatment market is 5.5% from 2019 to 2025.
Some of the key industry players are AbbVie, Inc., Alimera Sciences, Inc., Enzo Biochem, Inc., Amgen, Inc., Bausch Health Companies, Inc., Clearside Biomedical, Inc., EyePoint Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., TopiVert Ltd., and Novartis AG.
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.